The use of a non-glycosylated soluble Fc-gamma receptor for the treatment of multiple sclerosis, wherein the multiple sclerosis is a B cell mediated form of multiple sclerosis or an autoantibody driven form of multiple sclerosis. The receptor can be Fc-gamma RIIB/C (CD32) or FC-gamma RIIIA/B (CD16b).